The short version of reverse-phase HPLC fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-06-10. Anything still debated is marked as such rather than presented as settled.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
In its usual supplied form, the peptide is a white to off-white lyophilized powder that dissolves readily in water and in aqueous buffers. Powder keeps far longer than solution, so material is normally shipped and stored dry, then dissolved only when needed. Once in solution, the chain is subject to hydrolysis and the liquid supports microbial growth, and practical guidance generally treats the dissolved form as short-lived. Containers should stay sealed and desiccated, because the powder takes up moisture from air.
Long-term storage of the dry powder is typically described at minus twenty degrees Celsius or colder, while shorter holding periods may use ordinary refrigeration. Repeated warming and cooling cycles are discouraged because they stress the material and can promote aggregation or loss. Light exposure and residual moisture are both treated as avoidable sources of degradation, and working aliquots are often prepared to limit how many times a container is opened. Sealed vials with a desiccant are the usual container.
| Property | Value | Notes |
|---|---|---|
| Origin | Fragment of a protein found in human gastric juice | Sequence corresponds to a fifteen-residue portion of the parent protein |
| Sequence | GEPPPGKPADDAGLV | Single linear chain, fifteen amino acids |
| Reported molecular weight | About 1419 daltons | Value quoted consistently in supplier and review literature |
| Regulatory status | Not an approved human medicine in the US or EU | Handled and sold as a research chemical |
| Sports status | Listed as prohibited | Falls under non-approved-substance categories in anti-doping codes |
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
Confirmation of identity and purity relies on standard peptide analysis techniques. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities and serves as the most common purity assay. Mass spectrometry, often coupled to that chromatography step, provides an accurate molecular mass that can be matched against the expected value. Amino acid analysis or sequencing can be added for further confirmation. Because short peptides can be produced by different synthetic routes, laboratories usually report both a chromatographic purity percentage and a mass confirmation rather than a single figure.
BPC-157 is commonly supplied as a lyophilized powder, a freeze-dried solid that is reconstituted before use in laboratory work. As a short peptide, it dissolves readily in water and in aqueous buffer solutions, and stock solutions are typically prepared in water or a mild buffer. The chain contains several proline and acidic residues, which influence how it behaves in solution. Because the solid can take up moisture, weighing and handling are usually performed under low-humidity conditions. Its solubility class is described as freely soluble in water rather than requiring an organic solvent.
Dry powder is generally stored at low temperature, with minus twenty degrees Celsius or colder advised for extended retention. Reconstituted solutions are less stable than the solid form and are normally kept cold and shielded from repeated freeze-thaw cycles. Light exposure is avoided because some peptides degrade under ultraviolet radiation. The exact rate of degradation depends on concentration, pH, and the presence of salts, so a single shelf life does not apply to every preparation. Reported stability figures should be read as indicative of typical handling rather than as universal constants.
The sequence places several glycine and proline residues near the middle, which may influence how the chain folds in solution. The peptide is linear rather than cyclic, and it carries no disulfide bridges. Commercial material is commonly supplied as the acetate salt, although the free base and other counterion forms also appear. Because the term BPC-157 refers to a specific sequence, samples with slight sequence variants are chemically different substances. Published work generally treats the fifteen-residue sequence as the defining structure.
Physical descriptions in supplier documents and papers usually list the compound as a white to off-white powder. It dissolves readily in water and in common aqueous buffers, and solutions are often prepared fresh before an experiment. Molecular mass near 1419 daltons helps verify identity during mass spectrometry. The powder is somewhat hygroscopic, so moisture exposure can alter the measured mass of a sample. Purity is typically reported as a percentage from chromatographic analysis.
Some properties, such as the peptide's sequence and molecular mass, are firmly established. Other claims, particularly about mechanism and clinical benefit, remain open questions. Proposed mechanisms include effects on nitric oxide signaling and on cell migration, but these are hypotheses supported by limited evidence. Reviewers often note that the field lacks large controlled human trials. Positive animal findings are best treated as signals for further study rather than as settled conclusions.
Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.
=== Medications === Pentoxifylline is a useful add-on treatment to compression stockings and may also help by itself. It works by reducing platelet aggregation and thrombus formation. Gastrointestinal disturbances were reported as a potential adverse effect. Sulodexide, which reduces the formation of blood clots and reduces inflammation, may improve the healing of venous ulcers when taken in conjunction with proper local wound care. Further research is necessary to determine potential adverse effects, the effectiveness, and the dosing protocol for sulodexide treatment. An oral dose of aspirin is being investigated as a potential treatment option for people with venous ulcers. A 2016 Cochrane systematic review concluded that further research is necessary before this treatment option can be confirmed to be safe and effective. Oral zinc supplements have not been proven to be effective in aiding the healing of venous ulcers; however, more research is necessary to confirm these results. Treatments aimed at decreasing protease activity to promote healing in chronic wounds have been suggested; however, the benefit remains uncertain. There is also a lack of evidence on the effectiveness of testing for elevated proteases in venous ulcers and treating them with protease-modulating treatment. There is low certainty evidence that protease modulating matrix treatment is helpful in the healing of venous ulcers. Flavonoids may be useful for treating venous ulcers, but the evidence must be interpreted cautiously.
=== Reduced food waste === Worldwide, one third of the total food produced for consumption, around 1.6 billion tons per year, goes to waste. Food waste happens during processing, distribution and consumption. 3D food printing is a very promising way of reducing food waste during the phase of consumption, by utilizing food products like meat off-cuts, distorted fruits and vegetables, sea food by-products and perishables. These products can be processed in a suitable form for printing. Upprinting Food, a Dutch startup, has been blending and combining different ingredients from food waste to create purees which are then used as materials for 3D printing. Chefs are also creating different dishes from leftover food using 3D food printers.
=== Blood pressure === An early study showed that the intravenous injection of propionic acid into mice induced a brief (<5 min) hypotensive response as defined by drops in their mean arterial pressures. This response was reduced in mice that had one of their two Ffar3 genes knocked out and absent in mice that had both Ffar3 genes knocked out. A subsequent study reported that Ffar3 gene knockout mice developed abnormally high pulse pressures (i.e., systolic minus diastolic blood pressures) as well as increased amounts of cardiac collagen and elastin connective tissue and increased cardiac stiffness as evidenced by a reduced rate of heart muscle relaxation measured by pressure-volume loop analysis tau levels.
Sources: en.wikipedia.org
Compton had recently founded the American Research and Development Corporation (ARD) to spur the formation of new post-war industries. He introduced the founders to ARD's president, Georges Doriot. Doriot predicted the cancer treatment machines would be a commercial failure. Nevertheless, he perceived HVEC's leaders to be technically capable, and Compton persuaded him that ARD should have a startup with clear human benefits. Among more than 400 applications, Doriot selected the firm among ARD's first three investments. He offered the founders $200,000 in initial capitalization, leaving half the equity to them and their staff consultants. Compton arranged for HVEC to exclusively license MIT's Van de Graaff and Trump patents. Both Compton and Doriot served on the new company's board.
Sishen → Port of Saldanha (OREX), for transporting iron ore and manganese Ermelo → Richards Bay Coal Terminal, for transporting coal Northern Cape manganese fields → Gqeberha / Ngqura, for transporting manganese The country's "Core Rail Network", with a combined length of 4,481km, plays a major role in connecting the country's geographically separated economic hubs (metro areas), industrial hubs, inland logistics centers, and seaports. As of 2026, the network is as follows:
=== Zeek Braverman === Ezekiel "Zeek" Braverman (Craig T. Nelson) is the patriarch of the Braverman family, Camille's husband and the father of Adam, Sarah, Crosby, and Julia. He has dabbled in various careers, including being a soldier in Vietnam, having graduated from West Point in the class of 1962 (although in the season two episode "A House Divided" he is shown telling his grandson Max about going into basic training at Fort Benning, Georgia, which would imply he was enlisted; also, he would have been 19 or 20 when graduating West Point), an activist hippie, an aspiring actor, and a shrewd entrepreneur, but none lasted more than a few years. He is 67 at the start of the series (as he is said to be turning 72 in season 6), making him four years older than his wife, Camille. In the first season, it is revealed that he made a bad investment, causing him and his wife, Camille, financial hardship. Later, it is also revealed that he had an affair. He doesn't get along with his mother, Blanche. She turns 86 in season three, which means that she was about seventeen when Zeek was born, as he would have been 69 in season three. Zeek's health begins to decline throughout season 6, and he endures two hospital stays. Zeek dies peacefully in his home an unknown time after Sarah's wedding to Hank as Camille is looking at photos taken by Max. His ashes are spread in the musical montage that begins the last scene of the series finale.
The venom of the Red harvester ant was used to treat rheumatism, arthritis, and poliomyelitis via the immunological reaction produced by its sting. This technique, in which ants are allowed to sting affected areas in a controlled manner, is still used in some arid rural areas of Mexico. The silkworm, Bombyx mori, was also commonly consumed both as a regional food and for medicinal purposes in Central America after it was brought to the New World by the Spanish and Portuguese. Only the immatures are consumed. Boiled pupae were eaten to treat apoplexy, aphasy, bronchitis, pneumonia, convulsions, hemorrhages, and frequent urination. The excrement produced by the larvae is also eaten to improve circulation and alleviate the symptoms of cholera (intense vomiting and diarrhea).
Sources: en.wikipedia.org
It is not approved for human use in the United States or the European Union. Clinical material has been studied in a small number of early trials, mainly for inflammatory bowel conditions, and the compound remains investigational. Regulators treat marketed products as unapproved rather than as authorized drugs.
The peptide was named after a protein fraction found in human gastric juice, and the shorter form was called body protection compound. That phrase was shortened to the abbreviation BPC. The number 157 refers to a laboratory designation used in the original isolation work.
Its sequence corresponds to a segment of a protein present in gastric secretions, but the material supplied for research is made synthetically. No commercial product is purified from human or animal tissue. The synthetic route is used because it gives a defined chain length and a reproducible sequence.
The dry powder is the stable form and the dissolved form is comparatively fragile. Freezing a solution slows degradation but does not stop it, and repeated freezing and thawing adds further stress. Many laboratories therefore prepare small single-use portions rather than storing one large volume.